Ocular Therapeutix Inc

Financial Health of Ocular Therapeutix Inc

Comparing to competitors in the Biotechnology industry

Industry Rankings

Ocular Therapeutix Inc
Buy, Hold or Sell?

Should you buy, hold or sell Ocular Therapeutix Inc?

I guess you are interested in Ocular Therapeutix Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Ocular Therapeutix Inc

Let's start. I'm going to help you getting a better view of Ocular Therapeutix Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Show more...

Company's Financial Health
A deep dive into the books. How are the numbers doing? Is Ocular Therapeutix Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
Market Valuation
Finally, you now have an insight of how Ocular Therapeutix Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Ocular Therapeutix Inc. The closing price on 2022-12-07 was $2.8 per share. Is the company over- or underpriced?
Key Performance Indicators
A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.

Ocular Therapeutix Inc Daily Candlestick Chart

Summary

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

1.1. Profitability of Ocular Therapeutix Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Ocular Therapeutix Inc earns for each $1 of revenue.

Above 10% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
A Net Profit Margin of -202.2% means that $-2.02 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Ocular Therapeutix Inc:

The MRQ is -202.2%. The company is making a huge loss. -2
The TTM is -120.4%. The company is making a huge loss. -2

Trends

Current period		Compared to		+/-
MRQ	-202.2%	TTM	-120.4%	-81.8%
TTM	-120.4%	YOY	-293.2%	+172.9%
TTM	-120.4%	5Y	-1,550.5%	+1,430.1%
5Y	-1,550.5%	10Y	-2,485.4%	+935.0%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-202.2%	-223.6%	+21.4%
TTM	-120.4%	-281.7%	+161.3%
YOY	-293.2%	-344.8%	+51.6%
5Y	-1,550.5%	-450.1%	-1,100.4%
10Y	-2,485.4%	-541.0%	-1,944.4%

Measures how much net profit Ocular Therapeutix Inc earns for each $1 of revenue.

Revenue is the amount of profit Ocular Therapeutix Inc generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Ocular Therapeutix Inc earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Ocular Therapeutix Inc makes more profit. This shows the investor how efficiently Ocular Therapeutix Inc is operating in general and compared to other companies in the same industry. Ocular Therapeutix Inc operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Ocular Therapeutix Inc. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Ocular Therapeutix Inc is -2.02. This means that Ocular Therapeutix Inc earned $-2.02 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -223.6%.
What is the trend?
The trend is important because it shows you how Ocular Therapeutix Inc is performing over time. The most recent quarter might be important if Ocular Therapeutix Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ocular Therapeutix Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Ocular Therapeutix Inc with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Ocular Therapeutix Inc sells assets (profit will increase while costs remain the same).
It won’t show what part of Ocular Therapeutix Inc is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Ocular Therapeutix Inc

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Ocular Therapeutix Inc = -24,188
Total revenue MRQ Ocular Therapeutix Inc = 11,965
$-24,188 / $11,965 = -2.02 or -202.2%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Ocular Therapeutix Inc is using its assets to generate profit.

Above 5% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
-15.3% Return on Assets means that Ocular Therapeutix Inc generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Ocular Therapeutix Inc:

The MRQ is -15.3%. Using its assets, the company is very inefficient in making profit. -2
The TTM is -8.7%. Using its assets, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-15.3%	TTM	-8.7%	-6.6%
TTM	-8.7%	YOY	-8.5%	-0.2%
TTM	-8.7%	5Y	-17.4%	+8.8%
5Y	-17.4%	10Y	-16.3%	-1.1%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-15.3%	-9.9%	-5.4%
TTM	-8.7%	-8.9%	+0.2%
YOY	-8.5%	-9.3%	+0.8%
5Y	-17.4%	-11.7%	-5.7%
10Y	-16.3%	-12.7%	-3.6%

Shows how efficient Ocular Therapeutix Inc is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Ocular Therapeutix Inc is using its resources to generate profit. If the return on assets (-15.3%) from Ocular Therapeutix Inc are higher than the Biotechnology mean (-9.9%) that means Ocular Therapeutix Inc is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Ocular Therapeutix Inc is -15.3%. This means the company generated $-0.15 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -9.9%.
What is the trend?
The trend is important because it shows you how Ocular Therapeutix Inc is performing over time. The most recent quarter might be important if Ocular Therapeutix Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ocular Therapeutix Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Ocular Therapeutix Inc

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Ocular Therapeutix Inc = -24,188
Total assets MRQ (balance sheet) from Ocular Therapeutix Inc = 158,579
-24,188 / 158,579 = -0.15 or -15.3%

ROA is an important ratio as it will tell you how effectively Ocular Therapeutix Inc is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Ocular Therapeutix Inc is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
-52.3% Return on Equity means Ocular Therapeutix Inc generated $-0.52 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Ocular Therapeutix Inc:

The MRQ is -52.3%. Using its investors money, the company is very inefficient in making profit. -2
The TTM is -25.2%. Using its investors money, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-52.3%	TTM	-25.2%	-27.1%
TTM	-25.2%	YOY	-29.1%	+3.8%
TTM	-25.2%	5Y	-81.0%	+55.8%
5Y	-81.0%	10Y	-53.4%	-27.6%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-52.3%	-12.0%	-40.3%
TTM	-25.2%	-11.5%	-13.7%
YOY	-29.1%	-10.8%	-18.3%
5Y	-81.0%	-14.2%	-66.8%
10Y	-53.4%	-15.2%	-38.2%

Shows how efficient Ocular Therapeutix Inc is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Ocular Therapeutix Inc is -52.3%. This means Ocular Therapeutix Inc generated $-0.52 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -12.0%.
What is the trend?
The trend is important because it shows you how Ocular Therapeutix Inc is performing over time. The most recent quarter might be important if Ocular Therapeutix Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ocular Therapeutix Inc up to 10 years back (depending if Ocular Therapeutix Inc existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Ocular Therapeutix Inc

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Ocular Therapeutix Inc = -24,188
Shareholders equity (balance sheet) MRQ Ocular Therapeutix Inc = 46,229
-24,188 / 46,229 = -0.52 or -52.3%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Ocular Therapeutix Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Ocular Therapeutix Inc is operating .

Measures how much profit Ocular Therapeutix Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
An Operating Margin of -187.1% means the company generated $-1.87 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Ocular Therapeutix Inc:

The MRQ is -187.1%. The company is operating very inefficient. -2
The TTM is -106.6%. The company is operating very inefficient. -2

Trends

Current period		Compared to		+/-
MRQ	-187.1%	TTM	-106.6%	-80.6%
TTM	-106.6%	YOY	-274.7%	+168.1%
TTM	-106.6%	5Y	-1,473.5%	+1,367.0%
5Y	-1,473.5%	10Y	-2,401.0%	+927.4%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-187.1%	-207.3%	+20.2%
TTM	-106.6%	-271.0%	+164.4%
YOY	-274.7%	-325.9%	+51.2%
5Y	-1,473.5%	-454.0%	-1,019.5%
10Y	-2,401.0%	-537.1%	-1,863.9%

Measures how efficient Ocular Therapeutix Inc is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Ocular Therapeutix Inc is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Ocular Therapeutix Inc is -187.1%. This means that Ocular Therapeutix Inc earned $-1.87 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -207.3%.
What is the trend?
The trend is important because it shows you how Ocular Therapeutix Inc is performing over time. The most recent quarter might be important if Ocular Therapeutix Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ocular Therapeutix Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Ocular Therapeutix Inc

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Ocular Therapeutix Inc = -21,544
Total revenue MRQ Ocular Therapeutix Inc = 11,965
$-21,544 / $11,965 = -1.87 or -187.1%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Ocular Therapeutix Inc is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 2.80 means that the operating costs are $2.80 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Ocular Therapeutix Inc:

The MRQ is 2.801. The company is inefficient in keeping operating costs low. -1
The TTM is 2.561. The company is inefficient in keeping operating costs low. -1

Trends

Current period		Compared to		+/-
MRQ	2.801	TTM	2.561	+0.240
TTM	2.561	YOY	3.010	-0.449
TTM	2.561	5Y	15.784	-13.223
5Y	15.784	10Y	57.948	-42.164

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	2.801	2.871	-0.070
TTM	2.561	3.504	-0.943
YOY	3.010	3.604	-0.594
5Y	15.784	5.132	+10.652
10Y	57.948	6.371	+51.577

Measures how efficient Ocular Therapeutix Inc is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Ocular Therapeutix Inc is 280.1%. This means that Ocular Therapeutix Inc earned $2.80 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 2.87.
What is the trend?
The trend is important because it shows you how Ocular Therapeutix Inc is performing over time. The most recent quarter might be important if Ocular Therapeutix Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ocular Therapeutix Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Ocular Therapeutix Inc

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(1,073 +32,436) \ 11,965 = 2.80

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Ocular Therapeutix Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Ocular Therapeutix Inc is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 4.98 means the company has $4.98 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Ocular Therapeutix Inc:

The MRQ is 4.975. The company is very able to pay all its short-term debts. +2
The TTM is 6.417. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	4.975	TTM	6.417	-1.442
TTM	6.417	YOY	8.925	-2.508
TTM	6.417	5Y	6.348	+0.069
5Y	6.348	10Y	7.531	-1.183

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	4.975	5.117	-0.142
TTM	6.417	5.755	+0.662
YOY	8.925	5.854	+3.071
5Y	6.348	6.511	-0.163
10Y	7.531	6.222	+1.309

Measures if Ocular Therapeutix Inc is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Ocular Therapeutix Inc if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Ocular Therapeutix Inc is 4.98. This means Ocular Therapeutix Inc has $4.98 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 5.12.
What is the trend?
The trend is important because it shows you how Ocular Therapeutix Inc is performing over time. The most recent quarter might be important if Ocular Therapeutix Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ocular Therapeutix Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Ocular Therapeutix Inc

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
145,615 \ 29,269) = 4.98

The current ratio measures if Ocular Therapeutix Inc is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Ocular Therapeutix Inc is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Ocular Therapeutix Inc does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Ocular Therapeutix Inc is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Ocular Therapeutix Inc is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
A Quick Ratio of 4.81 means the company can pay off $4.81 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Ocular Therapeutix Inc:

The MRQ is 4.809. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 6.205. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	4.809	TTM	6.205	-1.396
TTM	6.205	YOY	8.704	-2.499
TTM	6.205	5Y	6.137	+0.068
5Y	6.137	10Y	8.907	-2.771

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	4.809	4.284	+0.525
TTM	6.205	4.664	+1.541
YOY	8.704	4.787	+3.917
5Y	6.137	5.218	+0.919
10Y	8.907	5.182	+3.725

Measures if Ocular Therapeutix Inc is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Ocular Therapeutix Inc can pay off its short term debts. This shows if Ocular Therapeutix Inc can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Ocular Therapeutix Inc is 4.81. This means that Ocular Therapeutix Inc can pay off $4.81 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 4.28.
What is the trend?
The trend is important because it shows you how Ocular Therapeutix Inc is performing over time. The most recent quarter might be important if Ocular Therapeutix Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ocular Therapeutix Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Ocular Therapeutix Inc

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Ocular Therapeutix Inc: (120,950 + +19,802) / 29,269 = 4.81

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Ocular Therapeutix Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Ocular Therapeutix Inc assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Ocular Therapeutix Inc to Biotechnology industry mean.
A Debt to Asset Ratio of 0.71 means that Ocular Therapeutix Inc assets are financed with 70.8% credit (debt) and the remaining percentage (100% - 70.8%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Ocular Therapeutix Inc:

The MRQ is 0.708. The company is able to pay all its debts by selling its assets. +1
The TTM is 0.618. The company is able to pay all its debts by selling its assets. +1

Trends

Current period		Compared to		+/-
MRQ	0.708	TTM	0.618	+0.090
TTM	0.618	YOY	0.654	-0.036
TTM	0.618	5Y	0.695	-0.077
5Y	0.695	10Y	0.488	+0.208

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.708	0.278	+0.430
TTM	0.618	0.277	+0.341
YOY	0.654	0.306	+0.348
5Y	0.695	0.367	+0.328
10Y	0.488	0.403	+0.085

Measures how much % of Ocular Therapeutix Inc assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Ocular Therapeutix Inc than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Ocular Therapeutix Inc to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Ocular Therapeutix Inc is 0.71. This means means that Ocular Therapeutix Inc is financed with 70.8% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 511.7%.
What is the trend?
The trend is important because it shows you how Ocular Therapeutix Inc is performing over time. The most recent quarter might be important if Ocular Therapeutix Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ocular Therapeutix Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Ocular Therapeutix Inc has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Ocular Therapeutix Inc

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
112,350 \ 158,579 = 70.8% or 0.71.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Ocular Therapeutix Inc is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
A Debt to Equity ratio of 243.0% means that company has $2.43 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Ocular Therapeutix Inc:

The MRQ is 2.430. The company is just not able to pay all its debts with equity.
The TTM is 1.685. The company is just able to pay all its debts with equity.

Trends

Current period		Compared to		+/-
MRQ	2.430	TTM	1.685	+0.745
TTM	1.685	YOY	1.931	-0.246
TTM	1.685	5Y	2.850	-1.165
5Y	2.850	10Y	1.689	+1.161

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	2.430	0.315	+2.115
TTM	1.685	0.317	+1.368
YOY	1.931	0.319	+1.612
5Y	2.850	0.403	+2.447
10Y	1.689	0.462	+1.227

Measures if Ocular Therapeutix Inc is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Ocular Therapeutix Inc is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Ocular Therapeutix Inc is 2.43. This means that Ocular Therapeutix Inc can pay off $2.43 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.32.
What is the trend?
The trend is important because it shows you how Ocular Therapeutix Inc is performing over time. The most recent quarter might be important if Ocular Therapeutix Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ocular Therapeutix Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Ocular Therapeutix Inc

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
112,350 \ 46,229 = 2.43 or 243.0%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Ocular Therapeutix Inc

2. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Ocular Therapeutix Inc generates.

Above 15 is considered overpriced but always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
A PE ratio of -13.21 means the investor is paying $-13.21 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Ocular Therapeutix Inc:

The EOD is -8.915. Company is losing money. -2
The MRQ is -13.213. Company is losing money. -2
The TTM is -53.152. Company is losing money. -2

Trends

Current period		Compared to		+/-
EOD	-8.915	MRQ	-13.213	+4.298
MRQ	-13.213	TTM	-53.152	+39.940
TTM	-53.152	YOY	156.111	-209.264
TTM	-53.152	5Y	5.924	-59.077
5Y	5.924	10Y	-29.343	+35.268

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-8.915	-8.986	+0.071
MRQ	-13.213	-9.792	-3.421
TTM	-53.152	-16.243	-36.909
YOY	156.111	-20.876	+176.987
5Y	5.924	-16.665	+22.589
10Y	-29.343	-14.732	-14.611

Measures how much money you pay for each share for every $1 in earnings Ocular Therapeutix Inc generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Ocular Therapeutix Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Ocular Therapeutix Inc is -13.21. This means the investor is paying $-13.21 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -9.79.
What is the trend?
The trend is important because it shows you how Ocular Therapeutix Inc is performing over time. The most recent quarter might be important if Ocular Therapeutix Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Ocular Therapeutix Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Ocular Therapeutix Inc

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
-24,188 \ 76,976 = EPS
PE ratio MRQ = -13.21

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Ocular Therapeutix Inc.

Lower is better.
A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Ocular Therapeutix Inc:

The MRQ is 47.859. Seems overpriced? -1
The TTM is 59.443. Seems overpriced? -1

Trends

Current period		Compared to		+/-
MRQ	47.859	TTM	59.443	-11.584
TTM	59.443	YOY	53.074	+6.369
TTM	59.443	5Y	691.650	-632.207
5Y	691.650	10Y	611.022	+80.628

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	47.859	-0.032	+47.891
TTM	59.443	0.004	+59.439
YOY	53.074	0.016	+53.058
5Y	691.650	0.006	+691.644
10Y	611.022	0.003	+611.019

PEG Ratio	Meaning
0.5	You can buy the stock cheap based on future growth
1	You pay a fair price based on future growth
2	The stock is overpriced based on future growth

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Ocular Therapeutix Inc is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 6.91 means the investor is paying $6.91 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Ocular Therapeutix Inc:

The EOD is 4.664. Neutral. Compare to industry.
The MRQ is 6.913. Seems overpriced? -1
The TTM is 5.900. Seems overpriced? -1

Trends

Current period		Compared to		+/-
EOD	4.664	MRQ	6.913	-2.249
MRQ	6.913	TTM	5.900	+1.013
TTM	5.900	YOY	15.601	-9.701
TTM	5.900	5Y	3.648	+2.252
5Y	3.648	10Y	7.305	-3.657

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	4.664	1.835	+2.829
MRQ	6.913	2.006	+4.907
TTM	5.900	2.774	+3.126
YOY	15.601	3.453	+12.148
5Y	3.648	2.713	+0.935
10Y	7.305	2.402	+4.903

2. Total Gains per Share

2.4. Latest News of Ocular Therapeutix Inc

Does Ocular Therapeutix Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Ocular Therapeutix Inc to keep up to date. Note: the news is often already included in the price.

Date	Title	Read
2022-11-13 13:10	These Analysts Just Made A Neat Downgrade To Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Forecasts	Read
2022-11-08 11:38	Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised)	Read

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Ocular Therapeutix Inc.

3.1. Institutions holding Ocular Therapeutix Inc

Institutions are holding 58.867% of the shares of Ocular Therapeutix Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2022-06-30	Opaleye Management Inc	7.7628	10.8265	5974800	0	0
2022-06-30	SUMMER ROAD LLC	7.7238	100	5944761	0	0
2022-06-30	Vanguard Group Inc	5.0652	0.0004	3898551	-296855	-7.0757
2022-09-30	Deltec Asset Management LLC	3.0191	2.3671	2323673	254360	12.292
2022-06-30	Citadel Advisors Llc	2.2399	0.0018	1723993	31657	1.8706
2022-09-30	Emerald Advisers, LLC	1.9573	0.3225	1506456	40754	2.7805
2022-06-30	State Street Corporation	1.8343	0.0003	1411827	-293107	-17.1917
2022-06-30	Geode Capital Management, LLC	1.7559	0.0008	1351425	-12545	-0.9197
2022-06-30	Federated Hermes Inc	1.5488	0.013	1192072	569792	91.5652
2022-09-30	Emerald Mutual Fund Advisers Trust	1.4059	0.2838	1082103	37371	3.5771
2022-06-30	MSD Partners, L.P.	1.3204	0.6988	1016302	1016302	0
2022-06-30	Endurant Capital Management LP	0.9877	1.0721	760228	-163735	-17.7209
2022-06-30	D. E. Shaw & Co LP	0.9725	0.0035	748465	134927	21.9916
2022-06-30	Altium Capital Management, LP	0.903	1.118	695000	0	0
2022-06-30	Northern Trust Corp	0.8674	0.0006	667581	-61579	-8.4452
2022-06-30	Cetera Investment Advisers	0.7785	0.0383	599150	32400	5.7168
2022-06-30	Banco Santander Central Hispano Sa	0.7222	0.0298	555884	555884	0
2022-06-30	UBS O'Connor LLC	0.6664	0.0361	512886	212886	70.962
2022-06-30	Bank of Montreal	0.6642	0.001	511195	300258	142.3449
2022-06-30	BMO Capital Markets Corp.	0.6642	0.001	511195	511195	0
Total		42.8595	116.8154	32987547	+2869965	+8.7%

3.2. Funds holding Ocular Therapeutix Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2022-10-31	Vanguard Total Stock Mkt Idx Inv	2.998	0.0007	2307462	0	0
2022-09-30	Vanguard Instl Ttl Stck Mkt Idx Tr	2.998	0.0009	2307462	0	0
2022-10-31	iShares Russell 2000 ETF	2.192	0.0114	1687111	5510	0.3277
2022-10-31	Vanguard Extended Market Index Investor	1.4922	0.005	1148481	8795	0.7717
2022-10-31	iShares Russell 2000 Growth ETF	0.8095	0.0233	623043	-2920	-0.4665
2022-08-31	Fidelity® Small Cap Index	0.778	0.0162	598828	13323	2.2755
2022-09-30	Emerald Growth A	0.6595	0.2676	507564	0	0
2022-09-30	Federated Hermes MDT Small Cap Core IS	0.5524	0.1668	425192	-122844	-22.4153
2022-09-30	Federated Hermes MDT SCC Institutional	0.5524	0.17	425192	-122844	-22.4153
2022-09-30	Principal SmallCap Growth I Instl	0.5354	0.0815	412090	-740	-0.1793
2022-09-30	State St Russell Sm/Mid Cp® Indx NL Cl C	0.5149	0.0055	396340	0	0
2022-09-30	Fidelity® Extended Market Index	0.4973	0.0057	382764	-25904	-6.3386
2022-09-30	Federated Hermes MDT Small Cap Growth IS	0.471	0.259	362542	-260957	-41.8536
2022-09-30	Federated Hermes MDT SCG Institutional	0.471	0.2638	362542	-260957	-41.8536
2022-09-30	State St Russell Sm Cap® Indx NL Cl C	0.3878	0.015	298493	10772	3.7439
2022-09-30	NT R2000 Growth Index Fund - NL	0.2969	0.0282	228534	-4076	-1.7523
2022-09-30	NT R2000 Index Fund - NL	0.2855	0.0145	219762	-4133	-1.846
2022-09-30	Empower Small Cap Growth/Emerald SP	0.2586	0.3197	199049	0	0
2022-10-31	Vanguard Russell 2000 ETF	0.2468	0.0113	189992	7306	3.9992
2022-09-30	AST Small-Cap Growth	0.2256	0.0728	173668	-65497	-27.3857
Total		17.2228	1.7389	13256111	-825166	-6.2%

3.3. Insider Transactions

Insiders are holding 1.184% of the shares of Ocular Therapeutix Inc.

Date	Owner	Type	Amount	Price	Post Transaction Amount
2022-11-07	Summer Road Llc	BUY	7328	3.5	6122089
2022-10-10	Summer Road Llc	BUY	10000	4	6104761
2022-09-29	Summer Road Llc	BUY	18800	4.04	6094761
2022-09-27	Summer Road Llc	BUY	130000	4.68	6074761
2022-02-23	Summer Road Llc	BUY	10000	4.8
2022-02-18	Summer Road Llc	BUY	40000	5
2022-01-27	Summer Road Llc	BUY	1477	5.2
2022-01-24	Summer Road Llc	BUY	44400	5.31
2022-01-20	Summer Road Llc	BUY	17948	5.7
2022-01-18	Summer Road Llc	BUY	6807	6
2022-01-13	Summer Road Llc	BUY	10000	6.2
2021-12-15	Summer Road Llc	BUY	15000	6.22
2021-12-13	Summer Road Llc	BUY	10510	6.5
2021-12-10	Summer Road Llc	BUY	30000	6.65
2021-12-08	Summer Road Llc	BUY	5300	6.75
2021-12-06	Summer Road Llc	BUY	55600	6.13
2021-08-20	Antony C Mattessich	BUY	5000	9.89	102900
2021-05-20	Richard L Md Lindstrom	SELL	10000	14.3	90000
2020-10-16	Summer Road Llc	BUY	437	10.48
2020-05-19	Summer Road Llc	BUY	363636	5.5

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Ocular Therapeutix Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	-0.197	-0.105	-46%	0.269	-173%	0.007	-3044%	0.015	-1413%
Book Value Growth	-	-	-0.423	-0.183	-57%	0.296	-243%	-0.306	-28%	-0.207	-51%
Book Value Per Share	-	-	0.600	0.858	-30%	0.986	-39%	0.521	+15%	0.583	+3%
Book Value Per Share Growth	-	-	-0.328	-0.151	-54%	0.272	-221%	-0.304	-7%	-0.206	-37%
Current Ratio	-	-	4.975	6.417	-22%	8.925	-44%	6.348	-22%	7.531	-34%
Debt To Asset Ratio	-	-	0.708	0.618	+15%	0.654	+8%	0.695	+2%	0.488	+45%
Debt To Equity Ratio	-	-	2.430	1.685	+44%	1.931	+26%	2.850	-15%	1.689	+44%
Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Eps	-	-	-0.314	-0.185	-41%	-0.287	-9%	-0.243	-23%	-0.186	-41%
Eps Growth	-	-	-0.276	-0.741	+169%	8.548	-103%	1.637	-117%	1.033	-127%
Gross Profit Margin	-	-	1.421	2.014	-29%	-0.281	+120%	1.074	+32%	1.072	+33%
Net Profit Margin	-	-	-2.022	-1.204	-40%	-2.932	+45%	-15.505	+667%	-24.854	+1129%
Operating Margin	-	-	-1.871	-1.066	-43%	-2.747	+47%	-14.735	+687%	-24.010	+1183%
Operating Ratio	-	-	2.801	2.561	+9%	3.010	-7%	15.784	-82%	57.948	-95%
Pb Ratio	4.664	-48%	6.913	5.900	+17%	15.601	-56%	3.648	+90%	7.305	-5%
Pe Ratio	-8.915	+33%	-13.213	-53.152	+302%	156.111	-108%	5.924	-323%	-29.343	+122%
Peg Ratio	-	-	47.859	59.443	-19%	53.074	-10%	691.650	-93%	611.022	-92%
Price Per Share	2.800	-48%	4.150	5.023	-17%	15.323	-73%	7.310	-43%	8.143	-49%
Price To Total Gains Ratio	-14.214	+33%	-21.067	14.469	-246%	98.092	-121%	-115.667	+449%	-105.143	+399%
Profit Growth	-	-	-22.416	-73.475	+228%	759.860	-103%	144.873	-115%	68.637	-133%
Quick Ratio	-	-	4.809	6.205	-22%	8.704	-45%	6.137	-22%	8.907	-46%
Return On Assets	-	-	-0.153	-0.087	-43%	-0.085	-44%	-0.174	+14%	-0.163	+7%
Return On Equity	-	-	-0.523	-0.252	-52%	-0.291	-44%	-0.810	+55%	-0.534	+2%
Revenue Growth	-	-	-0.025	-0.005	-79%	0.152	-117%	0.077	-133%	0.122	-121%
Total Gains Per Share	-	-	-0.197	-0.105	-46%	0.269	-173%	0.007	-3044%	0.015	-1413%
Total Gains Per Share Growth	-	-	-0.138	-0.492	+256%	-7.330	+5200%	-0.903	+553%	-0.913	+560%
Usd Book Value	-	-	46229000.000	69956500.000	-34%	81772500.000	-43%	42075200.000	+10%	45898550.000	+1%
Usd Book Value Change Per Share	-	-	-0.197	-0.105	-46%	0.269	-173%	0.007	-3044%	0.015	-1413%
Usd Book Value Per Share	-	-	0.600	0.858	-30%	0.986	-39%	0.521	+15%	0.583	+3%
Usd Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Usd Eps	-	-	-0.314	-0.185	-41%	-0.287	-9%	-0.243	-23%	-0.186	-41%
Usd Price Per Share	2.800	-48%	4.150	5.023	-17%	15.323	-73%	7.310	-43%	8.143	-49%
Usd Profit	-	-	-24188000.000	-14836500.000	-39%	-22078750.000	-9%	-18856850.000	-22%	-13845925.000	-43%
Usd Revenue	-	-	11965000.000	12431500.000	-4%	9640500.000	+24%	5252300.000	+128%	2772525.000	+332%
Usd Total Gains Per Share	-	-	-0.197	-0.105	-46%	0.269	-173%	0.007	-3044%	0.015	-1413%
	EOD	+3 -2	MRQ	TTM	+5 -28	YOY	+10 -23	5Y	+16 -17	10Y	+15 -18

4.2. Fundamental Score

Let's check the fundamental score of Ocular Therapeutix Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	-8.915
Price to Book Ratio (EOD)	Between	0-1	4.664
Net Profit Margin (MRQ)	Greater than	0	-2.022
Operating Margin (MRQ)	Greater than	0	-1.871
Quick Ratio (MRQ)	Greater than	1	4.809
Current Ratio (MRQ)	Greater than	1	4.975
Debt to Asset Ratio (MRQ)	Less than	1	0.708
Debt to Equity Ratio (MRQ)	Less than	1	2.430
Return on Equity (MRQ)	Greater than	0.15	-0.523
Return on Assets (MRQ)	Greater than	0.05	-0.153
Total			3/10 (30.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Ocular Therapeutix Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Open	Greater than	Close	2.900
Total			1/1 (100.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

		2021-09-30		2021-12-31		2022-03-31		2022-06-30		2022-09-30
Total Other Income Expense Net		22,186	-7,987	14,199	-8,908	5,291	-4,141	1,150	-3,794	-2,644

Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary

Total Assets	158,579
Total Liabilities	112,350
Total Stockholder Equity	46,229

	As reported
Total Liabilities	112,350
Total Stockholder Equity	+ 46,229
Total Assets	= 158,579

Assets

Total Assets	158,579
Total Current Assets	145,615
Long-term Assets	145,615

Total Current Assets

Total Current Assets (as reported)	145,615
Cash And Cash Equivalents	120,950
Net Receivables	19,802
Inventory	1,545
Other Current Assets	3,318
Total Current Assets (calculated)	145,615
+/-	0

Long-term Assets

Long-term Assets (as reported)	12,964
Property Plant Equipment	11,200
Other Assets	1,764
Long-term Assets (calculated)	12,964
+/-	0

Liabilities & Shareholders' Equity

Total Current Liabilities	29,269
Long-term Liabilities	83,081
Total Stockholder Equity	46,229

Total Current Liabilities

Total Current Liabilities (as reported)	29,269
Short-term Debt	1,744
Accounts payable	5,308
Other Current Liabilities	21,614
Total Current Liabilities (calculated)	28,666
+/-	603

Long-term Liabilities

Long-term Liabilities (as reported)	83,081
Long term Debt Total	53,344
Capital Lease Obligations Min Short Term Debt	4,610
Other Liabilities	25,127
Long-term Liabilities (calculated)	83,081
+/-	0

Total Stockholder Equity

Total Stockholder Equity (as reported)	46,229
Common Stock	8
Retained Earnings	-601,300
Capital Surplus	647,521
Total Stockholder Equity (calculated)	46,229
+/-	0

Other

Capital Stock	8
Cash and Short Term Investments	120,950
Common Stock Shares Outstanding	76,976
Common Stock Total Equity	8
Current Deferred Revenue	603
Liabilities and Stockholders Equity	158,579
Net Debt	-61,252
Net Invested Capital	99,573
Net Tangible Assets	46,229
Net Working Capital	116,346
Short Long Term Debt Total	59,698

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

> Total Assets

25,285
0
0
0
19,146
15,080
23,974
83,878
78,193
71,497
129,470
119,319
110,306
100,432
89,901
82,347
74,939
90,697
79,675
64,399
55,431
76,685
70,459
70,270
73,043
101,490
89,742
88,710
78,740
72,857
107,260
98,219
261,863
243,040
230,707
217,739
204,887
187,622
173,071
158,579

158,579

173,071

187,622

204,887

217,739

230,707

243,040

261,863

98,219

107,260

72,857

78,740

88,710

89,742

101,490

73,043

70,270

70,459

76,685

55,431

64,399

79,675

90,697

74,939

82,347

89,901

100,432

110,306

119,319

129,470

71,497

78,193

83,878

23,974

15,080

19,146

25,285

> Total Current Assets

0
0
0
0
18,014
13,811
22,594
82,274
76,183
69,470
126,639
115,898
106,983
97,097
84,974
76,824
69,898
83,276
68,328
52,453
43,339
64,476
58,472
58,274
56,193
79,172
65,436
69,636
60,170
55,153
90,293
81,903
246,160
228,132
216,523
203,932
191,300
174,652
160,322
145,615

145,615

160,322

174,652

191,300

203,932

216,523

228,132

246,160

81,903

90,293

55,153

60,170

69,636

65,436

79,172

56,193

58,274

58,472

64,476

43,339

52,453

68,328

83,276

69,898

76,824

84,974

97,097

106,983

115,898

126,639

69,470

76,183

82,274

22,594

13,811

18,014

Cash And Cash Equivalents

23,854
0
0
0
17,505
12,750
19,944
80,892
37,393
12,523
78,686
41,198
30,784
46,212
48,170
52,234
32,936
54,682
63,049
51,165
41,538
62,911
56,834
56,861
54,062
76,251
61,765
65,414
54,437
48,152
84,294
70,642
228,057
209,378
191,860
179,281
164,164
145,417
134,539
120,950

120,950

134,539

145,417

164,164

179,281

191,860

209,378

228,057

70,642

84,294

48,152

54,437

65,414

61,765

76,251

54,062

56,861

56,834

62,911

41,538

51,165

63,049

54,682

32,936

52,234

48,170

46,212

30,784

41,198

78,686

12,523

37,393

80,892

19,944

12,750

17,505

23,854

Short-term Investments

60
0
0
0
60
60
60
60
37,435
54,900
45,036
72,445
74,280
49,244
35,717
23,513
35,209
25,697
3,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

3,000

25,697

35,209

23,513

35,717

49,244

74,280

72,445

45,036

54,900

37,435

Net Receivables

0
0
0
0
269
306
61
54
329
352
164
189
193
227
223
243
250
244
211
278
226
170
285
240
201
276
615
1,114
2,548
3,429
2,874
7,779
12,252
13,631
18,734
19,552
21,135
23,207
20,482
19,802

19,802

20,482

23,207

21,135

19,552

18,734

13,631

12,252

7,779

2,874

3,429

2,548

1,114

615

276

201

240

285

170

226

278

211

244

250

243

223

227

193

189

164

352

329

306

269

Inventory

0
0
0
0
0
87
109
117
133
158
145
147
134
127
149
126
113
96
90
127
122
139
131
102
217
265
762
895
954
1,107
1,067
1,154
1,201
1,123
1,112
1,222
1,250
1,358
1,500
1,545

1,545

1,500

1,358

1,250

1,222

1,112

1,123

1,201

1,154

1,067

1,107

954

895

762

265

217

102

131

139

122

127

113

126

149

127

134

147

145

158

133

117

109

> Long-term Assets

0
0
0
0
1,132
1,269
1,380
1,604
2,010
2,027
2,831
3,421
3,323
3,335
4,927
5,523
5,041
7,421
11,347
11,946
12,092
12,209
11,987
11,996
16,850
22,318
24,306
19,074
18,570
17,704
16,967
16,316
15,703
14,908
14,184
13,807
13,587
12,970
12,749
12,964

12,964

12,749

12,970

13,587

13,807

14,184

14,908

15,703

16,316

16,967

17,704

18,570

19,074

24,306

22,318

16,850

11,996

11,987

12,209

12,092

11,946

11,347

7,421

5,041

5,523

4,927

3,335

3,323

3,421

2,831

2,027

2,010

1,604

1,380

1,269

1,132

Property Plant Equipment

785
0
0
0
904
1,041
1,152
1,376
1,782
1,799
2,603
3,193
3,095
3,107
3,199
3,795
3,313
5,693
9,619
10,218
10,478
10,595
10,373
10,382
10,236
15,704
17,542
17,310
16,806
15,940
15,203
14,552
13,939
13,144
12,420
12,043
11,823
11,206
10,985
11,200

11,200

10,985

11,206

11,823

12,043

12,420

13,144

13,939

14,552

15,203

15,940

16,806

17,310

17,542

15,704

10,236

10,382

10,373

10,595

10,478

10,218

9,619

5,693

3,313

3,795

3,199

3,107

3,095

3,193

2,603

1,799

1,782

1,376

1,152

1,041

904

785

Long-term Assets Other

0
0
0
0
228
228
228
228
228
228
228
228
228
228
1,728
1,728
1,728
1,728
1,728
1,728
1,614
1,614
1,614
1,614
6,614
6,614
6,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764
1,764

1,764

6,764

6,614

1,614

1,728

228

> Total Liabilities

6,073
0
0
0
4,274
3,933
19,054
18,276
19,497
19,424
20,358
20,511
20,718
20,262
19,453
20,053
22,931
26,792
31,650
28,477
29,284
27,501
24,730
24,753
37,168
75,842
81,484
77,409
82,370
83,516
101,916
102,345
185,768
159,632
150,460
130,399
116,888
107,827
107,268
112,350

112,350

107,268

107,827

116,888

130,399

150,460

159,632

185,768

102,345

101,916

83,516

82,370

77,409

81,484

75,842

37,168

24,753

24,730

27,501

29,284

28,477

31,650

26,792

22,931

20,053

19,453

20,262

20,718

20,511

20,358

19,424

19,497

18,276

19,054

3,933

4,274

6,073

> Total Current Liabilities

3,475
0
0
0
3,342
2,069
4,489
3,379
5,874
7,227
9,591
11,181
5,378
6,003
6,419
8,243
8,300
8,656
13,130
10,945
13,426
13,151
11,899
13,406
9,159
8,614
10,127
11,005
12,029
11,112
13,803
22,906
26,664
27,437
21,550
25,158
26,337
23,960
26,113
29,269

29,269

26,113

23,960

26,337

25,158

21,550

27,437

26,664

22,906

13,803

11,112

12,029

11,005

10,127

8,614

9,159

13,406

11,899

13,151

13,426

10,945

13,130

8,656

8,300

8,243

6,419

6,003

5,378

11,181

9,591

7,227

5,874

3,379

4,489

2,069

3,342

3,475

Short-term Debt

0
0
0
0
0
0
1,085
0
1,354
2,860
4,370
5,883
15,272
1,161
2,466
3,772
1,549
897
2,444
3,993
5,545
6,071
6,082
6,094
0
675
0
0
0
2,074
4,146
6,206
8,290
9,711
1,487
1,554
1,624
1,696
1,771
1,744

1,744

1,771

1,696

1,624

1,554

1,487

9,711

8,290

6,206

4,146

2,074

675

6,094

6,082

6,071

5,545

3,993

2,444

897

1,549

3,772

2,466

1,161

15,272

5,883

4,370

2,860

1,354

1,085

Short Long Term Debt

0
0
0
0
0
0
0
0
1,354
0
0
0
15,272
0
2,466
3,772
1,549
897
17,818
3,993
5,545
6,071
6,082
6,094
0
675
0
0
0
2,074
4,146
6,206
8,290
8,290
0
0
0
0
0
0

8,290

6,206

4,146

2,074

675

6,094

6,082

6,071

5,545

3,993

17,818

897

1,549

3,772

2,466

15,272

1,354

Accounts payable

583
0
0
0
545
996
1,525
649
1,316
2,195
2,812
1,624
1,957
2,063
1,611
1,680
2,116
3,754
6,307
2,599
3,571
3,477
2,137
2,777
2,965
3,902
4,044
3,461
3,268
2,839
2,650
3,238
2,709
4,152
3,881
4,246
4,592
3,420
3,703
5,308

5,308

3,703

3,420

4,592

4,246

3,881

4,152

2,709

3,238

2,650

2,839

3,268

3,461

4,044

3,902

2,965

2,777

2,137

3,477

3,571

2,599

6,307

3,754

2,116

1,680

1,611

2,063

1,957

1,624

2,812

2,195

1,316

649

1,525

996

545

583

Other Current Liabilities

1,086
0
0
0
2,547
823
2,714
2,480
3,016
1,922
2,284
3,591
3,379
2,779
2,342
2,791
4,635
4,005
4,379
4,353
4,310
3,603
3,680
4,535
6,194
4,712
6,083
7,544
8,761
6,199
7,007
13,462
15,665
13,574
16,182
19,358
20,121
17,636
19,450
21,614

21,614

19,450

17,636

20,121

19,358

16,182

13,574

15,665

13,462

7,007

6,199

8,761

7,544

6,083

4,712

6,194

4,535

3,680

3,603

4,310

4,353

4,379

4,005

4,635

2,791

2,342

2,779

3,379

3,591

2,284

1,922

3,016

2,480

2,714

823

2,547

1,086

> Long-term Liabilities

0
0
0
0
932
1,864
14,565
14,897
13,623
12,197
10,767
9,330
15,340
14,259
13,034
11,810
14,631
18,136
18,520
17,532
15,858
14,350
12,831
11,347
28,009
67,228
71,357
66,404
70,341
72,404
88,113
79,439
159,104
132,195
128,910
105,241
90,551
83,867
81,155
83,081

83,081

81,155

83,867

90,551

105,241

128,910

132,195

159,104

79,439

88,113

72,404

70,341

66,404

71,357

67,228

28,009

11,347

12,831

14,350

15,858

17,532

18,520

18,136

14,631

11,810

13,034

14,259

15,340

9,330

10,767

12,197

13,623

14,897

14,565

1,864

932

Long term Debt Total

0
0
0
0
0
0
13,594
14,776
13,511
12,094
10,673
9,249
15,272
14,204
12,992
11,778
14,094
16,821
15,374
13,924
12,471
11,014
9,548
8,073
24,788
47,857
48,796
48,098
49,312
48,286
47,322
42,766
41,243
39,729
50,239
50,822
0
52,058
52,695
53,344

53,344

52,695

52,058

50,822

50,239

39,729

41,243

42,766

47,322

48,286

49,312

48,098

48,796

47,857

24,788

8,073

9,548

11,014

12,471

13,924

15,374

16,821

14,094

11,778

12,992

14,204

15,272

9,249

10,673

12,094

13,511

14,776

13,594

Capital Lease Obligations Min Short Term Debt

0
0
0
0
0
0
-1,085
0
-1,354
-2,860
-4,370
-5,883
-15,272
-1,161
-2,466
-3,772
-1,549
-897
-2,444
-3,993
-5,545
-6,071
-6,082
-6,094
0
7,909
10,517
10,279
10,031
7,697
5,348
3,000
616
-1,121
6,770
6,355
5,924
5,472
4,999
4,610

4,610

4,999

5,472

5,924

6,355

6,770

-1,121

616

3,000

5,348

7,697

10,031

10,279

10,517

7,909

-6,094

-6,082

-6,071

-5,545

-3,993

-2,444

-897

-1,549

-3,772

-2,466

-1,161

-15,272

-5,883

-4,370

-2,860

-1,354

-1,085

Warrants

0
0
0
0
0
0
74,355
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

74,355

Long-term Liabilities Other

0
0
0
0
0
0
852
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,909
9,493
9,206
8,905
8,590
8,256
7,909
19,548
19,169
18,770
18,355
0
18,575
17,999
18,143

18,143

17,999

18,575

18,355

18,770

19,169

19,548

7,909

8,256

8,590

8,905

9,206

9,493

7,909

852

Deferred Long Term Liability

0
0
0
0
0
0
119
121
112
103
94
81
68
55
42
32
537
1,315
3,146
3,608
3,387
3,336
3,283
3,274
3,221
11,462
13,068
9,100
12,124
15,528
32,535
28,764
98,313
73,297
59,901
36,064
0
13,234
10,461
11,594

11,594

10,461

13,234

36,064

59,901

73,297

98,313

28,764

32,535

15,528

12,124

9,100

13,068

11,462

3,221

3,274

3,283

3,336

3,387

3,608

3,146

1,315

537

103

112

121

119

> Total Stockholder Equity

19,212
0
0
0
14,872
11,147
4,920
65,602
58,696
52,073
109,112
98,808
89,588
80,170
70,448
62,294
52,008
63,905
48,025
35,922
26,147
49,184
45,729
45,517
35,875
25,648
8,258
11,301
-3,630
-10,659
5,344
-4,126
76,095
83,408
80,247
87,340
87,999
79,795
65,803
46,229

46,229

65,803

79,795

87,999

87,340

80,247

83,408

76,095

-4,126

5,344

-10,659

-3,630

11,301

8,258

25,648

35,875

45,517

45,729

49,184

26,147

35,922

48,025

63,905

52,008

62,294

70,448

80,170

89,588

98,808

109,112

52,073

58,696

65,602

4,920

11,147

14,872

19,212

Common Stock

0
0
0
0
0
2
0
2
2
2
2
2
2
2
2
2
3
3
3
3
3
4
4
4
4
4
4
5
5
5
6
6
8
8
8
8
8
8
8
8

Retained Earnings Total Equity

-601,300

-577,112

-558,346

-541,954

-544,611

-536,130

-539,251

-453,639

-441,695

-405,127

-383,615

-357,598

-338,820

-314,367

-297,243

-279,844

-264,834

-251,030

-237,265

-224,163

-208,596

-189,902

-173,879

-161,057

-151,461

-140,016

-129,176

-118,539

-107,015

-97,006

-89,428

-81,474

-74,180

Accumulated Other Comprehensive Income

-10,019

-7,627

-5,341

-4,836

-3,818

-2,939

-2,221

-1,768

-1,675

Capital Surplus

0
0
0
0
0
0
4,745
147,074
148,122
149,077
216,133
217,361
218,830
220,184
221,897
223,344
225,889
253,813
256,618
260,082
263,409
300,210
310,559
325,357
333,114
340,011
347,074
368,894
379,980
394,463
447,033
449,507
615,338
619,530
624,850
629,286
0
638,133
642,907
647,521

647,521

642,907

638,133

629,286

624,850

619,530

615,338

449,507

447,033

394,463

379,980

368,894

347,074

340,011

333,114

325,357

310,559

300,210

263,409

260,082

256,618

253,813

225,889

223,344

221,897

220,184

218,830

217,361

216,133

149,077

148,122

147,074

4,745

Treasury Stock

Other Stockholders Equity

0
0
0
0
77,327
80,701
79,100
147,074
150,343
149,077
216,125
217,345
221,701
220,184
221,907
223,349
229,702
253,804
256,618
264,918
268,750
300,210
310,559
325,357
340,741
340,011
347,074
368,894
389,999
394,463
447,033
449,507
615,338
619,530
624,850
629,286
633,795
638,133
642,907
647,521

647,521

642,907

638,133

633,795

629,286

624,850

619,530

615,338

449,507

447,033

394,463

389,999

368,894

347,074

340,011

340,741

325,357

310,559

300,210

268,750

264,918

256,618

253,804

229,702

223,349

221,907

220,184

221,701

217,345

216,125

149,077

150,343

147,074

79,100

80,701

77,327

Balance Sheet

Currency in USD. All numbers in thousands.

	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Accounts Payable	4,592	2,709	3,268	2,965	3,571	2,116	1,957	1,316	545	583
Accumulated Other Comprehensive Income	-	-	-10,019	-7,627	-5,341	-3,818	-2,939	-2,221	-1,675	-1,271
Additional Paid In Capital	-	-	-	-	0	0	0	0	-	-
Capital Lease Obligations	7,548	8,906	10,031	-	-	-	-	-	-	-
Capital Stock	8	8	5	4	-	-	-	-	-	-
Capital Surpluse	-	615,338	379,980	333,114	263,409	225,889	218,830	148,122	-	-
Cash	164,164	228,057	54,437	54,062	41,538	32,936	30,784	37,393	17,505	23,854
Cash And Short Term Investments	164,164	228,057	54,437	54,062	41,538	68,145	105,064	74,828	17,505	23,854
Common Stock	8	8	5	4	3	3	2	2	-	-
Common Stock Shares Outstanding	82,162	60,752	45,273	38,115	28,818	24,816	23,244	10,653	14,605	2,953
Common Stock Total Equity	-	8	5	4	3	3	2	2	-	-
Current Deferred Revenue	13,000	-	-	-	-	-	42	188	250	-
Deferred Long Term Liab	-	98,313	12,124	3,221	3,387	537	68	112	-	-
Good Will	-	-	-	-	0	0	0	0	-	-
Intangible Assets	-	-	-	-	0	0	0	0	-	-
Inventory	1,250	1,201	954	217	122	113	134	133	-	-
Liabilities And Stockholders Equity	204,887	261,863	78,740	73,043	55,431	74,939	110,306	78,193	19,146	25,285
Long Term Debt	51,435	41,243	49,312	24,788	12,471	14,094	15,272	13,511	651	2,259
Long Term Debt Total	-	41,243	49,312	24,788	12,471	14,094	15,272	13,511	-	-
Net Debt	-105,181	-169,618	4,906	-29,274	-23,522	-17,293	58,768	-22,528	-15,048	-19,789
Net Invested Capital	139,434	125,628	45,682	60,663	44,163	-	-	-	-	-
Net Receivables	21,135	12,252	2,548	201	226	250	193	329	269	45
Net Tangible Assets	87,999	76,095	-3,630	35,875	26,147	52,008	89,588	58,696	-	-
Net Working Capital	164,963	219,496	48,141	47,034	29,913	-	-	-	-	-
Non Current Assets Total	13,587	15,703	18,570	16,850	12,092	5,041	3,323	2,010	1,132	1,023
Non Current Liabilities Other	-	19,548	8,905	-	0	0	-	-	-	-
Non Current Liabilities Total	90,551	159,104	70,341	28,009	15,858	14,631	15,340	13,623	932	2,598
Non Currrent Assets Other	1,764	1,764	1,764	6,614	1,614	1,728	228	228	228	238
Noncontrolling Interest In Consolidated Entity	-	-	-	-	0	0	0	0	-	-
Other Assets	1,764	7,608	1,764	6,614	1,614	1,728	228	228	228	238
Other Current Assets	4,751	4,650	2,231	1,713	1,453	1,390	1,592	893	240	363
Other Current Liab	20,121	14,307	7,635	6,194	4,310	4,635	3,379	3,016	2,547	2,892
Other Liab	33,192	110,313	12,124	3,221	3,387	537	68	112	281	339
Other Stockholder Equity	633,795	615,338	389,999	340,741	268,750	229,702	221,701	150,343	77,327	67,946
Preferred Stock Total Equity	-	-	-	-	0	0	0	0	74,344	65,823
Property Plant And Equipment Gross	-	13,939	16,806	10,236	10,478	3,313	3,095	1,782	904	785
Property Plant And Equipment Net	11,823	13,939	16,806	10,236	10,478	3,313	3,095	1,782	904	785
Property Plant Equipment	11,823	8,095	10,151	10,236	10,478	3,313	3,095	1,782	904	785
Retained Earnings	-545,804	-539,251	-383,615	-297,243	-237,265	-173,879	-129,176	-89,428	-60,780	-47,463
Retained Earnings Total Equity	-	-539,251	-383,615	-297,243	-237,265	-173,879	-129,176	-89,428	-	-
Short Long Term Debt	-	8,290	-	-	5,545	1,549	15,272	1,354	-	-
Short Long Term Debt Total	58,983	58,439	59,343	24,788	18,016	15,643	89,552	14,865	2,457	4,065
Short Term Debt	1,624	9,648	1,126	-	5,545	1,549	15,272	1,354	-	-
Short Term Investments	-	-	-	-	0	35,209	74,280	37,435	60	60
Temporary Equity Redeemable Noncontrolling Interests	-	-	-	-	0	0	0	0	-	-
Total Assets	204,887	261,863	78,740	73,043	55,431	74,939	110,306	78,193	19,146	25,285
Total Current Assets	191,300	246,160	60,170	56,193	43,339	69,898	106,983	76,183	18,014	24,262
Total Current Liabilities	26,337	26,664	12,029	9,159	13,426	8,300	5,378	5,874	3,342	3,475
Total Liab	116,888	185,768	82,370	37,168	29,284	22,931	20,718	19,497	4,274	6,073
Total Permanent Equity	-	-	-	-	0	0	0	0	-	-
Total Stockholder Equity	87,999	76,095	-3,630	35,875	26,147	52,008	89,588	58,696	14,872	19,212
Treasury Stock	-	-	-	-	0	0	0	0	-	-

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31
Accounts Payable	5,308	3,703	3,420	4,592	4,246	3,881	4,152	2,709	3,238	2,650	2,839	3,268	3,461	4,044	3,902	2,965	2,777	2,137	3,477	3,571	2,599	6,307	3,754	2,116	1,680	1,611	2,063	1,957	1,624	2,812	2,195	1,316	649	1,525	996	545	-	-	-	583
Accumulated Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-	-10,019	-10,019	-	-	-7,627	-7,627	0	0	-5,341	-5,341	-4,836	0	-3,818	-3,818	0	0	-2,939	-2,939	0	0	-2,221	-2,221	0	0	-1,768	-1,675	-	-	-	-
Additional Paid In Capital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Capital Lease Obligations	6,354	6,770	7,168	7,548	7,909	8,257	8,590	8,906	9,206	9,494	9,771	10,031	10,279	10,517	8,584	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Stock	8	8	8	8	8	8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Surpluse	647,521	642,907	638,133	-	629,286	624,850	619,530	615,338	449,507	447,033	394,463	379,980	368,894	347,074	340,011	333,114	325,357	310,559	300,210	263,409	260,082	256,618	253,813	225,889	223,344	221,897	220,184	218,830	217,361	216,133	149,077	148,122	147,074	4,745	-	-	-	-	-	-
Cash	120,950	134,539	145,417	164,164	179,281	191,860	209,378	228,057	70,642	84,294	48,152	54,437	65,414	61,765	76,251	54,062	56,861	56,834	62,911	41,538	51,165	63,049	54,682	32,936	52,234	48,170	46,212	30,784	41,198	78,686	12,523	37,393	80,892	19,944	12,750	17,505	-	-	-	23,854
Cash And Short Term Investments	120,950	134,539	145,417	164,164	179,281	191,860	209,378	228,057	70,642	84,294	48,152	54,437	65,414	61,765	76,251	54,062	56,861	56,834	62,911	41,538	51,165	66,049	80,379	68,145	75,747	83,887	95,456	105,064	113,643	123,722	67,423	74,828	80,892	19,944	12,750	17,505	-	-	-	-
Common Stock	8	8	8	8	8	8	8	8	6	6	5	5	5	4	4	4	4	4	4	3	3	3	3	3	2	2	2	2	2	2	2	2	2	0	2	-	-	-	-	-
Common Stock Shares Outstanding	76,976	82,534	82,515	82,386	85,447	82,094	87,246	70,614	68,762	57,368	51,901	48,490	52,714	42,910	44,174	41,094	39,018	37,525	34,793	29,658	29,088	29,026	27,644	24,889	24,854	24,770	24,752	24,733	24,714	22,167	21,363	21,289	15,166	3,045	15,300	2,624	2,624	2,596	15,300	-
Common Stock Total Equity	8	8	8	-	8	8	8	8	6	6	5	5	5	4	4	4	4	4	4	3	3	3	3	3	2	2	2	2	2	2	2	2	2	0	2	-	-	-	-	-
Current Deferred Revenue	603	1,189	1,208	13,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	42	83	125	250	188	250	250	250	250	-	-	-	-
Deferred Long Term Liab	11,594	10,461	13,234	-	36,064	59,901	73,297	98,313	28,764	32,535	15,528	12,124	9,100	13,068	11,462	3,221	3,274	3,283	3,336	3,387	3,608	3,146	1,315	537	32	42	55	68	81	94	103	112	121	119	-	-	-	-	-	-
Good Will	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Intangible Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Inventory	1,545	1,500	1,358	1,250	1,222	1,112	1,123	1,201	1,154	1,067	1,107	954	895	762	265	217	102	131	139	122	127	90	96	113	126	149	127	134	147	145	158	133	117	109	87	-	-	-	-	-
Liabilities And Stockholders Equity	158,579	173,071	187,622	204,887	217,739	230,707	243,040	261,863	98,219	107,260	72,857	78,740	88,710	89,742	101,490	73,043	70,270	70,459	76,685	55,431	64,399	79,675	90,697	74,939	82,347	89,901	100,432	110,306	119,319	129,470	71,497	78,193	83,878	23,974	15,080	19,146	-	-	-	-
Long Term Debt	53,344	52,695	52,058	51,435	50,822	50,239	39,729	41,243	42,766	47,322	48,286	49,312	48,098	48,796	47,857	24,788	8,073	9,548	11,014	12,471	13,924	15,374	16,821	14,094	11,778	12,992	14,204	15,272	9,249	10,673	12,094	13,511	14,776	13,594	1,851	651	-	-	-	2,259
Long Term Debt Total	53,344	52,695	52,058	-	50,822	50,239	39,729	41,243	42,766	47,322	48,286	49,312	48,098	48,796	47,857	24,788	8,073	9,548	11,014	12,471	13,924	15,374	16,821	14,094	11,778	12,992	14,204	15,272	9,249	10,673	12,094	13,511	14,776	13,594	-	-	-	-	-	-
Net Debt	-61,252	-75,074	-86,191	-105,181	-120,550	-133,364	-152,769	-178,524	-21,670	-32,826	2,208	4,906	-7,037	-2,452	-19,810	-29,274	-42,694	-41,204	-45,826	-23,522	-33,248	-45,231	-36,964	-17,293	-36,684	-32,712	-30,847	58,768	-26,066	-63,643	2,431	-22,528	-66,116	-5,265	-10,747	-15,048	-	-	-	-
Net Invested Capital	99,573	118,498	131,853	139,434	138,162	130,486	131,427	125,628	44,846	56,812	39,701	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Receivables	19,802	20,482	23,207	21,135	19,552	18,734	13,631	12,252	7,779	2,874	3,429	2,548	1,114	615	276	201	240	285	170	226	278	211	244	250	243	223	227	193	189	164	352	329	54	61	306	269	-	-	-	-
Net Tangible Assets	46,229	65,803	79,795	87,999	87,340	80,247	83,408	76,095	-4,126	5,344	-10,659	-3,630	11,301	8,258	25,648	35,875	45,517	45,729	49,184	26,147	35,922	48,025	63,905	52,008	62,294	70,448	80,170	89,588	98,808	109,112	52,073	58,696	65,602	4,920	-	-	-	-	-	-
Net Working Capital	116,346	134,209	150,692	164,963	178,774	194,973	200,695	219,496	58,997	76,490	44,041	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non Current Assets Total	12,964	12,749	12,970	13,587	13,807	14,184	14,908	15,703	16,316	16,967	17,704	18,570	19,074	24,306	22,318	16,850	11,996	11,987	12,209	12,092	11,946	11,347	7,421	5,041	5,523	4,927	3,335	3,323	3,421	2,831	2,027	2,010	1,604	1,380	1,269	1,132	-	-	-	-
Non Current Liabilities Other	18,143	17,999	18,575	-	18,355	18,770	19,169	19,548	7,909	8,256	8,590	8,905	9,206	9,493	7,909	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	852	-	-	-	-	-	-
Non Current Liabilities Total	83,081	81,155	83,867	90,551	105,241	128,910	132,195	159,104	79,439	88,113	72,404	70,341	66,404	71,357	67,228	28,009	11,347	12,831	14,350	15,858	17,532	18,520	18,136	14,631	11,810	13,034	14,259	15,340	9,330	10,767	12,197	13,623	14,897	14,565	1,864	932	-	-	-	-
Non Currrent Assets Other	1,764	1,764	1,764	1,764	1,764	1,764	1,764	1,764	1,764	1,764	1,764	1,764	1,764	6,764	6,614	6,614	1,614	1,614	1,614	1,614	1,728	1,728	1,728	1,728	1,728	1,728	228	228	228	228	228	228	228	228	228	228	-	-	-	-
Noncontrolling Interest In Consolidated Entity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Other Assets	1,764	1,764	1,764	1,764	1,764	1,764	1,764	7,608	1,764	1,764	1,764	1,764	1,764	6,764	6,614	6,614	1,614	1,614	1,614	1,614	1,728	1,728	1,728	1,728	1,728	1,728	228	228	228	228	228	228	228	228	228	228	-	-	-	238
Other Current Assets	3,318	3,801	4,670	4,751	3,877	4,817	4,000	4,650	2,328	2,058	2,465	2,231	2,213	2,294	2,380	1,713	1,071	1,222	1,256	1,453	883	1,978	2,557	1,390	708	715	1,287	1,592	1,919	2,608	1,537	893	1,211	2,480	668	240	-	-	-	303
Other Current Liab	21,614	19,450	17,636	20,121	19,358	16,182	13,574	15,665	13,462	7,007	6,199	8,761	7,544	6,083	4,712	6,194	4,535	3,680	3,603	4,310	4,353	4,379	4,005	4,635	2,791	2,342	2,779	3,379	3,591	2,284	1,922	3,016	2,480	2,714	823	2,547	-	-	-	1,086
Other Liab	25,127	23,461	26,337	33,192	48,064	71,901	85,297	110,313	28,764	32,535	15,528	12,124	9,100	13,068	11,462	3,221	3,274	3,283	3,336	3,387	3,608	3,146	1,315	537	32	42	55	68	81	94	103	112	121	971	408	281	-	-	-	339
Other Stockholder Equity	647,521	642,907	638,133	633,795	629,286	624,850	619,530	615,338	449,507	447,033	394,463	389,999	368,894	347,074	340,011	340,741	325,357	310,559	300,210	268,750	264,918	256,618	253,804	229,702	223,349	221,907	220,184	221,701	217,345	216,125	149,077	150,343	147,074	79,100	80,701	77,327	-	-	-	-
Preferred Stock Total Equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	74,355	74,350	74,344	-	-	-	65,823
Property Plant And Equipment Gross	-	-	-	-	-	12,420	13,144	13,939	14,552	15,203	15,940	16,806	17,310	17,542	15,704	10,236	10,382	10,373	10,595	10,478	10,218	9,619	5,693	3,313	3,795	3,199	3,107	3,095	3,193	2,603	1,799	1,782	1,376	1,152	1,041	904	-	-	-	-
Property Plant And Equipment Net	11,200	10,985	11,206	11,823	12,043	12,420	13,144	13,939	14,552	15,203	15,940	16,806	17,310	17,542	15,704	10,236	10,382	10,373	10,595	10,478	10,218	9,619	5,693	3,313	3,795	3,199	3,107	3,095	3,193	2,603	1,799	1,782	1,376	1,152	1,041	904	-	-	-	-
Property Plant Equipment	7,196	10,985	6,614	11,823	12,043	12,420	7,527	8,095	8,490	8,934	9,473	10,151	10,474	10,532	10,548	10,236	10,382	10,373	10,595	10,478	10,218	9,619	5,693	3,313	3,795	3,199	3,107	3,095	3,193	2,603	1,799	1,782	1,376	1,152	1,041	904	-	-	-	785
Retained Earnings	-601,300	-577,112	-558,346	-545,804	-541,954	-544,611	-536,130	-539,251	-453,639	-441,695	-405,127	-383,615	-357,598	-338,820	-314,367	-297,243	-279,844	-264,834	-251,030	-237,265	-224,163	-208,596	-189,902	-173,879	-161,057	-151,461	-140,016	-129,176	-118,539	-107,015	-97,006	-89,428	-81,474	-74,180	-67,788	-60,780	-	-	-	-
Retained Earnings Total Equity	-601,300	-577,112	-558,346	-	-541,954	-544,611	-536,130	-539,251	-453,639	-441,695	-405,127	-383,615	-357,598	-338,820	-314,367	-297,243	-279,844	-264,834	-251,030	-237,265	-224,163	-208,596	-189,902	-173,879	-161,057	-151,461	-140,016	-129,176	-118,539	-107,015	-97,006	-89,428	-81,474	-74,180	-	-	-	-	-	-
Short Long Term Debt	-	-	-	-	-	-	8,290	8,290	6,206	4,146	2,074	-	-	-	675	-	6,094	6,082	6,071	5,545	3,993	17,818	897	1,549	3,772	2,466	-	15,272	-	-	-	1,354	-	-	-	-	-	-	-	-
Short Long Term Debt Total	59,698	59,465	59,226	58,983	58,731	58,496	56,609	49,533	48,972	51,468	50,360	59,343	58,377	59,313	56,441	24,788	14,167	15,630	17,085	18,016	17,917	17,818	17,718	15,643	15,550	15,458	15,365	89,552	15,132	15,043	14,954	14,865	14,776	14,679	2,003	2,457	-	-	-	-
Short Term Debt	1,744	1,771	1,696	1,624	1,554	1,487	9,711	8,290	6,206	4,146	2,074	-	-	-	675	-	6,094	6,082	6,071	5,545	3,993	2,444	897	1,549	3,772	2,466	1,161	15,272	5,883	4,370	2,860	1,354	-	1,085	-	-	-	-	-	-
Short Term Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	3,000	25,697	35,209	23,513	35,717	49,244	74,280	72,445	45,036	54,900	37,435	60	60	60	60	-	-	-	60
Temporary Equity Redeemable Noncontrolling Interests	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Total Assets	158,579	173,071	187,622	204,887	217,739	230,707	243,040	261,863	98,219	107,260	72,857	78,740	88,710	89,742	101,490	73,043	70,270	70,459	76,685	55,431	64,399	79,675	90,697	74,939	82,347	89,901	100,432	110,306	119,319	129,470	71,497	78,193	83,878	23,974	15,080	19,146	-	-	-	25,285
Total Current Assets	145,615	160,322	174,652	191,300	203,932	216,523	228,132	246,160	81,903	90,293	55,153	60,170	69,636	65,436	79,172	56,193	58,274	58,472	64,476	43,339	52,453	68,328	83,276	69,898	76,824	84,974	97,097	106,983	115,898	126,639	69,470	76,183	82,274	22,594	13,811	18,014	-	-	-	-
Total Current Liabilities	29,269	26,113	23,960	26,337	25,158	21,550	27,437	26,664	22,906	13,803	11,112	12,029	11,005	10,127	8,614	9,159	13,406	11,899	13,151	13,426	10,945	13,130	8,656	8,300	8,243	6,419	6,003	5,378	11,181	9,591	7,227	5,874	3,379	4,489	2,069	3,342	-	-	-	3,475
Total Liab	112,350	107,268	107,827	116,888	130,399	150,460	159,632	185,768	102,345	101,916	83,516	82,370	77,409	81,484	75,842	37,168	24,753	24,730	27,501	29,284	28,477	31,650	26,792	22,931	20,053	19,453	20,262	20,718	20,511	20,358	19,424	19,497	18,276	19,054	3,933	4,274	-	-	-	6,073
Total Permanent Equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Total Stockholder Equity	46,229	65,803	79,795	87,999	87,340	80,247	83,408	76,095	-4,126	5,344	-10,659	-3,630	11,301	8,258	25,648	35,875	45,517	45,729	49,184	26,147	35,922	48,025	63,905	52,008	62,294	70,448	80,170	89,588	98,808	109,112	52,073	58,696	65,602	4,920	11,147	14,872	-	-	-	19,212
Treasury Stock	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Warrants	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	74,355	-	-	-	-	-	-

Cash Flow

Currency in USD. All numbers in thousands.

	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Begin Period Cash Flow	229,821	56,201	60,676	43,152	32,936	30,784	37,393	17,505	23,854	5,330
Capital Expenditures	1,194	841	2,238	1,889	8,252	1,919	1,778	1,260	387	203
Cash And Cash Equivalents Changes	-	173,619	-4,475	17,524	8,602	2,152	-6,609	19,888	-	-
Cash Flows Other Operating	-	9,267	-629	-260	45	924	-53	36	-	-
Change In Cash	-63,893	173,620	-4,475	17,524	8,602	2,152	-6,609	19,888	-6,349	18,524
Change In Working Capital	-2,901	1,175	-1,875	585	3,550	2,076	503	2,162	-240	726
Change Receivables	-	-9,704	-2,347	25	24	-57	136	-19	-	-
Change To Account Receivables	-8,883	-9,704	-2,347	25	24	-57	136	-60	-224	77
Change To Inventory	-49	-247	-737	-95	-9	21	-1	-133	-	-
Change To Liabilities	2,796	1,859	1,838	915	3,490	1,188	421	507	-	-
Change To Netincome	-58,517	93,720	4,456	7,483	7,313	7,188	4,299	2,644	-	-
Change To Operating Activities	3,235	-422	1,085	1,451	2,603	2,313	166	1,910	-	-
Depreciation	2,421	2,773	2,530	2,286	1,625	881	754	547	404	404
Dividends Paid	-	-	-	-	0	0	0	0	-	-
End Period Cash Flow	165,928	229,821	56,201	60,676	41,538	32,936	30,784	37,393	17,505	23,854
Free Cash Flow	-66,744	-54,395	-79,816	-51,116	-58,725	-35,920	-35,521	-21,756	-13,032	-12,788
Investments	-1,194	-841	-2,238	-1,889	35,200	38,985	-36,858	-37,326	-	-
Issuance Of Capital Stock	0	224,682	37,537	61,571	-	-	-	-	-	-
Net Borrowings	-445	-445	37,275	6,375	2,400	2,400	397	12,371	-	-
Net Income	-6,553	-155,636	-86,372	-59,978	-63,386	-44,703	-39,748	-28,648	-13,317	-14,093
Other Cashflows From Financing Activities	7,018	6,533	37,804	12,726	4,070	-287	1,027	11,725	8,501	28,204
Other Cashflows From Investing Activities	-	-	-	-	119	-1,498	7	60	-	-
Other Non Cash Items	-73,494	90,603	-620	397	417	1,789	108	2,799	32	135
Sale Purchase Of Stock	-	228,014	38,066	62,265	30,199	1,104	66,068	66,599	-	-
Total Cash From Financing Activities	2,851	228,014	75,341	68,640	32,008	585	65,703	78,970	6,683	27,295
Total Cash From Operating Activities	-65,550	-53,554	-77,578	-49,227	-50,473	-34,001	-33,743	-20,496	-12,645	-12,585
Total Cashflows From Investing Activities	-1,194	-841	-2,238	-1,889	27,067	35,568	-38,569	-38,586	-	3,814

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31
Begin Period Cash Flow	136,303	147,181	165,928	181,045	193,624	211,142	229,821	72,406	86,058	49,916	56,201	67,178	68,529	82,865	60,676	58,475	58,448	64,525	43,152	51,165	63,049	54,682	32,936	52,234	48,170	46,212	30,784	41,198	78,686	12,523	37,393	80,892	19,944	12,750	17,505	21,617	25,030	20,001	23,854	-
Capital Expenditures	794	495	276	631	276	129	158	253	214	125	249	601	419	493	725	479	473	556	381	564	2,036	3,998	1,654	680	869	243	127	473	76	875	354	441	274	248	297	206	109	51	21	203
Cash And Cash Equivalents Changes	-13,589	-10,878	-18,747	-	-12,579	-17,518	-18,679	157,414	-13,652	36,142	-6,285	-10,977	-1,351	-14,336	22,189	2,201	27	-6,077	21,373	-9,627	-11,884	8,367	21,746	-19,298	4,064	1,958	15,428	-10,414	-37,488	66,163	-24,870	-	-	-	-	-	-	-	-	-
Cash Flows Other Operating	315	636	1,287	-	841	-911	561	9,596	-351	328	-306	-85	17	165	-726	-642	151	34	197	-462	1,095	579	-1,167	40	19	560	305	267	429	-919	170	-	-	-	-	-	-	-	-	-
Change In Cash	-13,589	-10,878	-18,747	-15,117	-12,579	-17,518	-18,679	157,415	-13,652	36,142	-6,285	-10,977	-1,351	-14,336	22,189	2,201	27	-6,077	21,373	-9,627	-11,884	8,367	21,746	-19,298	4,064	1,958	15,428	-10,414	-37,488	66,163	-24,870	-43,499	60,948	7,194	-4,755	-4,112	-3,413	5,029	-3,853	-
Change In Working Capital	6,270	4,625	-5,054	-1,030	2,689	-4,232	-328	5,911	-1,667	1,124	-4,193	-315	385	221	-2,166	1,088	1,611	-912	-1,202	-17	-1,141	5,346	-638	1,708	629	-152	-109	628	263	79	-467	1,259	66	961	-124	-216	452	-90	-386	-
Change Receivables	680	2,725	-2,072	-	-818	-5,103	-1,379	-4,473	-4,905	555	-881	-1,434	-499	-339	-75	39	45	-115	56	52	-67	33	6	-7	-20	4	-34	-4	-25	188	-23	-	-	-	-	-	-	-	-	-
Change To Account Receivables	680	2,725	-2,072	-1,583	-818	-5,103	-1,379	-4,473	-4,905	555	-881	-1,434	-499	-339	-75	39	45	-115	56	52	-67	33	6	-7	-20	4	-34	-4	-25	188	-23	-275	7	245	-37	-236	-15	26	1	77
Change To Inventory	-45	-142	-108	-28	-110	11	78	-47	-87	40	-153	-59	-133	-497	-48	-115	29	8	-17	5	-37	6	17	13	23	-22	7	13	-2	13	-25	-16	-8	-22	-87	-	-	-	-	-
Change To Liabilities	2,963	182	-4,161	1,366	175	-268	412	835	3,676	201	-2,853	1,263	670	1,035	-1,130	1,806	1,386	-839	-1,438	388	-2,132	4,728	506	1,662	619	-706	-387	352	-139	797	-589	445	-	-	-	-	-	-	-	-
Change To Netincome	5,372	2,713	-2,747	-10,843	-18,922	-7,954	-21,930	71,653	-1,835	18,833	5,069	4,977	-2,541	3,301	-1,281	1,949	1,873	1,830	1,831	2,109	1,745	1,757	1,702	2,971	1,353	1,515	1,349	1,023	1,231	1,107	938	5,443	-	-	-	-	-	-	-	-
Change To Operating Activities	2,021	1,860	-3,072	-785	3,442	1,128	-550	-1,004	2,426	1,079	-2,923	1,086	1,759	1,044	-2,804	957	1,001	72	-579	2,603	1,722	3,044	-1,167	2,313	7	572	-	166	-	-	-	1,910	-	-	-	-	-	-	-	-
Depreciation	509	552	557	570	594	611	646	667	665	707	734	674	669	411	776	582	573	566	565	528	482	354	261	253	216	207	205	200	194	187	173	164	139	151	93	125	92	94	93	-
Dividends Paid	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
End Period Cash Flow	122,714	136,303	147,181	165,928	181,045	193,624	211,142	229,821	72,406	86,058	49,916	56,201	67,178	68,529	82,865	60,676	58,475	58,448	64,525	41,538	51,165	63,049	54,682	32,936	52,234	48,170	46,212	30,784	41,198	78,686	12,523	37,393	80,892	19,944	12,750	17,505	21,617	25,030	20,001	23,854
Free Cash Flow	-13,963	-11,371	-18,876	-15,784	-13,258	-20,185	-17,517	-6,499	-13,872	-14,921	-19,103	-20,068	-19,963	-19,674	-20,111	-14,127	-11,346	-12,789	-12,854	-10,947	-16,418	-15,129	-16,231	-8,292	-8,200	-10,045	-9,383	-9,109	-9,776	-9,403	-7,233	-6,067	-6,607	-4,760	-4,322	-3,663	-2,959	-3,012	-3,398	-
Investments	-794	-495	-276	-631	-276	-129	-158	-253	-214	-125	-249	-601	-419	-493	-725	-	-	-	-	35,200	3,000	22,700	9,500	-11,699	12,184	13,500	25,000	-1,673	-27,511	9,826	-17,500	-37,326	-	-	-	-	-	-	-	-
Net Borrowings	-	-	-	-	-	1,638	-2,083	-2,083	-2,083	-2,083	-	-	-	-70	37,345	10,489	-1,543	-1,542	-1,029	2,400	-1,029	-1,029	2,400	2,400	-130	-195	-	739	-	-171	-171	12,604	-	-	-	-	-	-	-	-
Net Income	-24,188	-18,766	-12,542	-3,850	2,657	-8,481	3,121	-85,612	-11,944	-36,568	-21,512	-26,017	-18,778	-24,453	-17,124	-17,399	-15,010	-13,804	-13,765	-13,102	-15,567	-18,694	-16,023	-12,822	-9,596	-11,445	-10,840	-10,637	-11,524	-10,009	-7,578	-7,954	-7,294	-6,392	-7,008	-3,505	-3,522	-3,090	-3,200	-
Other Cashflows From Financing Activities	374	493	129	667	679	4,751	1,196	1,938	538	728	128	201	33	224	37,346	12,261	73	126	266	625	-56	-4	3,505	-51	78	3	-189	1,244	-167	65,733	-137	-106	67,555	13,773	21	5	-109	8,496	-21	-
Other Cashflows From Investing Activities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	114	5	0	0	-1,500	2	-1,500	0	60	0	7	0	60	0	0	-	-	-	-	-	-
Other Non Cash Items	1,225	-1,568	-5,770	-14,684	-22,680	-12,246	-23,884	70,684	-2,648	18,115	4,452	4,238	-4,989	2,945	-2,814	132	80	87	98	99	94	106	118	1,526	51	73	139	-163	136	63	72	-72	149	211	2,511	14	7	5	6	-
Sale Purchase Of Stock	374	493	129	-	679	1,028	-275	163,913	220	51,063	12,818	9,091	18,612	5,408	4,955	5,839	12,916	8,254	35,256	1,206	1,726	993	26,274	823	78	198	5	133	-3	65,904	34	69,518	69,518	0	-	-	-	-	-	-
Total Cash From Financing Activities	374	493	129	667	679	2,667	-1,162	163,913	220	51,063	12,818	9,091	18,612	5,338	42,300	16,328	11,373	6,712	34,227	1,206	1,529	796	28,477	693	78	3	-189	308	-201	65,733	-137	-106	67,555	11,954	-433	-449	-454	8,041	-455	27,295
Total Cash From Operating Activities	-13,169	-10,876	-18,600	-15,153	-12,982	-20,056	-17,359	-6,246	-13,658	-14,796	-18,854	-19,467	-19,544	-19,181	-19,386	-13,648	-10,873	-12,233	-12,473	-10,383	-14,382	-11,131	-14,577	-7,612	-7,331	-9,802	-9,256	-8,636	-9,700	-8,528	-6,879	-5,626	-6,333	-4,512	-4,025	-3,457	-2,850	-2,961	-3,377	-
Total Cashflows From Investing Activities	-794	-495	-276	-631	-276	-129	-158	-253	-214	-125	-249	-601	-419	-493	-725	-479	-473	-556	-381	-450	969	18,702	7,846	-12,379	11,317	11,757	24,873	-2,086	-27,587	8,958	-17,854	-38,586	-819	-545	-	-	-	-	-	3,814

Income Statement

Currency in USD. All numbers in thousands.

	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Cost Of Revenue	4,406	2,083	2,325	465	457	443	319	91	-	7
Depreciation And Amortization	2,421	2,773	2,530	2,286	1,625	881	754	547	404	404
Ebit	118	-148,868	-80,271	-58,239	-61,494	-43,023	-38,024	-27,529	-12,876	-13,716
Ebitda	2,539	-146,095	-77,741	-55,953	-59,869	-42,142	-37,270	-26,982	-12,472	-13,312
Gross Profit	39,116	15,320	1,902	1,525	1,466	1,444	1,431	681	-	3
Income Before Tax	-6,553	-155,636	-86,372	-59,978	-63,386	-44,703	-39,748	-28,648	-13,317	-14,093
Income Tax Expense	-	-	-	0	0	0	0	0	-	-
Interest Expense	6,671	6,768	6,101	1,739	1,892	1,680	1,724	1,119	441	377
Interest Income	33	168	1,229	879	424	304	1,558	-	-	-
Net Income	-6,553	-155,636	-86,372	-59,978	-63,386	-44,703	-39,748	-28,648	-13,317	-14,093
Net Income Applicable To Common Shares	-6,553	-155,636	-86,372	-59,978	-63,386	-44,703	-39,748	-28,659	-	-
Net Income From Continuing Ops	-6,553	-155,636	-86,372	-59,978	-63,386	-44,703	-39,748	-28,648	-	-
Net Interest Income	-6,638	-6,600	-4,872	-860	-1,468	-1,376	-	-	-	-
Non Operating Income Net Other	-	-86,021	5,531	879	429	303	173	-435	-	-
Operating Income	-78,037	-62,847	-85,802	-59,118	-61,923	-43,326	-38,197	-27,094	-12,903	-13,671
Other Operating Expenses	121,559	80,250	90,029	61,108	63,846	45,213	39,947	27,866	12,903	13,681
Preferred Stock And Other Adjustments	-	-	-	-	-	-	-	11	-	-
Reconciled Depreciation	2,421	2,773	2,530	2,286	1,625	-	-	-	-	-
Research Development	50,083	28,694	41,091	36,915	30,880	27,065	26,611	18,880	10,517	11,540
Selling And Marketing Expenses	35,190	26,614	24,491	4,942	17,000	6,701	3,852	1,982	625	657
Selling General Administrative	31,880	22,859	22,122	18,786	15,509	11,004	9,165	6,913	1,761	1,477
Total Operating Expenses	117,153	78,167	87,704	60,643	63,389	44,770	39,628	27,775	12,903	13,674
Total Other Income Expense Net	71,484	-92,789	-570	-860	-1,463	-1,377	-1,551	-1,554	-414	-422
Total Revenue	43,522	17,403	4,227	1,990	1,923	1,887	1,750	772	-	10

	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31
Cost Of Revenue	1,073	1,155	1,300	1,108	1,310	1,096	892	680	450	134	819	839	806	552	128	117	115	153	80	113	125	104	115	127	112	105	99	92	91	80	56	30	32	20	9	0	0	0	0	13,277
Depreciation And Amortization	509	552	557	570	594	611	646	667	665	707	734	674	669	411	776	582	573	566	565	528	482	354	261	253	216	207	205	200	194	187	173	164	139	151	93	125	92	94	93	-
Discontinued Operations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ebit	-22,391	-17,070	-10,859	-2,170	4,315	-6,826	4,800	-83,886	-10,229	-34,874	-19,879	-24,212	-17,127	-22,826	-16,106	-17,025	-14,586	-13,349	-13,279	-12,612	-15,076	-18,226	-15,580	-12,404	-9,170	-11,027	-10,422	-10,229	-11,118	-9,604	-7,073	-7,547	-6,882	-6,135	-6,965	-3,414	-3,428	-2,983	-3,051	0
Ebitda	-21,882	-16,518	-10,302	-1,600	4,909	-6,215	5,446	-83,219	-9,564	-34,167	-19,145	-23,538	-16,458	-22,415	-15,330	-16,443	-14,013	-12,783	-12,714	-12,084	-14,594	-17,872	-15,319	-12,151	-8,954	-10,820	-10,217	-10,029	-10,924	-9,417	-6,900	-7,383	-6,743	-5,984	-6,872	-3,289	-3,336	-2,889	-2,958	-
Effect Of Accounting Charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Extraordinary Items	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gross Profit	10,892	11,111	11,887	11,200	10,843	10,622	6,450	6,669	5,426	1,435	1,790	1,417	23	98	364	387	383	495	260	374	398	334	360	384	365	336	359	344	338	379	370	475	111	77	18	0	0	0	0	0
Income Before Tax	-24,188	-18,766	-12,542	-3,850	2,657	-8,481	3,121	-85,612	-11,944	-36,568	-21,512	-26,017	-18,778	-24,453	-17,124	-17,399	-15,010	-13,804	-13,765	-13,102	-15,567	-18,694	-16,023	-12,822	-9,596	-11,445	-10,840	-10,637	-11,524	-10,009	-7,578	-7,954	-7,294	-6,392	-7,008	-3,505	-3,522	-3,090	-3,200	0
Income Tax Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Interest Expense	1,797	1,696	1,683	1,680	1,658	1,655	1,679	1,726	1,715	1,694	1,633	1,805	1,651	1,627	1,018	374	424	455	486	490	491	468	443	418	426	418	418	408	406	405	505	407	412	257	43	91	94	107	149	377
Interest Income	285	73	18	6	7	8	12	6	6	17	139	213	308	379	2,534	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-24,188	-18,766	-12,542	-3,850	2,657	-8,481	3,121	-85,612	-11,944	-36,568	-21,512	-26,017	-18,778	-24,453	-17,124	-17,399	-15,010	-13,804	-13,765	-13,102	-15,567	-18,694	-16,023	-12,822	-9,596	-11,445	-10,840	-10,637	-11,524	-10,009	-7,578	-7,954	-7,294	-6,392	-7,008	-3,505	-3,522	-3,090	-3,200	0
Net Income Applicable To Common Shares	-24,188	-18,766	-12,542	-3,850	2,657	-8,481	3,121	-85,612	-11,944	-36,568	-21,512	-26,017	-18,778	-24,453	-17,124	-17,399	-15,010	-13,804	-13,765	-13,102	-15,567	-18,694	-16,023	-12,822	-9,596	-11,445	-10,840	-10,637	-11,524	-10,009	-7,578	-28,659	-7,294	-6,397	0	0	0	0	0	0
Net Income From Continuing Ops	-24,188	-18,766	-12,542	-3,850	2,657	-8,481	3,121	-85,612	-11,944	-36,568	-21,512	-26,017	-18,778	-24,453	-17,124	-17,399	-15,010	-13,804	-13,765	-13,102	-15,567	-18,694	-16,023	-12,822	-9,596	-11,445	-10,840	-10,637	-11,524	-10,009	-7,578	-28,648	-7,294	-6,392	0	0	0	0	0	0
Net Interest Income	-1,512	-1,623	-1,665	-1,674	-1,651	-1,647	-1,667	-1,720	-1,709	-1,677	-1,494	-1,592	-1,343	-1,248	-689	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non Operating Income Net Other	-847	2,846	6,974	-	23,844	13,405	25,028	-69,543	3,777	-16,990	-3,265	-2,811	6,017	-1,227	3,552	258	230	215	176	104	120	113	92	68	68	80	87	46	56	31	40	-	-106	-189	-	-	-	-	-	-
Non Recurring	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating Income	-21,544	-19,916	-17,833	-18,049	-19,529	-20,231	-20,228	-14,343	-14,006	-17,884	-16,614	-21,401	-23,144	-21,599	-19,658	-17,283	-14,816	-13,564	-13,455	-12,716	-15,196	-18,339	-15,672	-12,472	-9,238	-11,107	-10,509	-10,275	-11,174	-9,635	-7,113	-7,547	-6,776	-5,946	-6,825	-3,419	-3,435	-2,989	-3,060	0
Other Items	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	33,509	32,182	31,020	30,357	31,682	31,949	27,570	21,692	19,882	19,453	19,223	23,657	23,973	22,249	20,150	17,787	15,314	14,212	13,795	13,203	15,719	18,777	16,147	12,983	9,715	11,548	10,967	10,711	11,603	10,094	7,539	8,052	6,919	6,043	6,852	3,419	3,435	2,989	3,060	0
Reconciled Depreciation	509	552	557	570	594	611	646	667	665	707	734	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research Development	13,719	13,100	13,100	12,578	12,719	13,859	10,927	7,624	6,951	8,021	6,098	10,125	10,235	9,414	11,317	10,258	9,685	8,745	8,227	7,908	8,126	8,117	6,729	7,328	5,686	6,978	7,073	6,886	8,263	6,743	4,719	5,148	4,482	4,292	4,958	2,842	2,784	2,404	2,487	11,540
Selling And Marketing Expenses	10,186	10,140	9,063	9,136	9,576	8,391	8,086	6,811	6,520	6,153	7,130	7,142	6,777	7,225	3,347	2,291	1,067	867	717	903	3,238	6,832	6,027	2,526	1,294	1,492	1,389	1,143	798	1,041	870	658	479	535	310	197	148	143	137	-
Selling General Administrative	8,531	7,787	7,557	7,535	8,077	8,603	7,665	6,577	5,961	5,145	5,176	5,551	6,155	5,058	5,358	5,121	4,447	4,447	4,771	4,279	4,230	3,724	3,276	3,002	2,623	2,973	2,406	2,590	2,451	2,230	1,894	2,216	1,926	1,196	1,575	380	503	442	436	0
Total Operating Expenses	32,436	31,027	29,720	29,249	30,372	30,853	26,678	21,012	19,432	19,319	18,404	22,818	23,167	21,697	20,022	17,670	15,199	14,059	13,715	13,090	15,594	18,673	16,032	12,856	9,603	11,443	10,868	10,619	11,512	10,014	7,483	8,022	6,887	6,023	6,843	3,419	3,435	2,989	3,060	0
Total Other Income Expense Net	-2,644	1,150	5,291	14,199	22,186	11,750	23,349	-71,269	2,062	-18,684	-4,898	-4,616	4,366	-2,854	2,534	-116	-194	-240	-310	-386	-371	-355	-351	-350	-358	-338	-331	-362	-350	-374	-465	-407	-518	-446	-183	-86	-87	-101	-140	0
Total Revenue	11,965	12,266	13,187	12,308	12,153	11,718	7,342	7,349	5,876	1,569	2,609	2,256	829	650	492	504	498	648	340	487	523	438	475	511	477	441	458	436	429	459	426	505	143	97	27	0	0	0	0	10

Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue	43,522
Cost of Revenue	-4,406
Gross Profit	39,116	39,116

Operating Income (+$)
Gross Profit	39,116
Operating Expense	-117,153
Operating Income	-78,037	-78,037

Operating Expense (+$)
Research Development	50,083
Selling General Administrative	31,880
Selling And Marketing Expenses	35,190
Operating Expense	117,153	117,153

Net Interest Income (+$)
Interest Income	33
Interest Expense	-6,671
Net Interest Income	-6,638	-6,638

Pretax Income (+$)
Operating Income	-78,037
Net Interest Income	-6,638
Other Non-Operating Income Expenses	-
Income Before Tax (EBT)	-6,553	-149,521 EBIT - interestExpense = -6,553 -6,553 118
Interest Expense	6,671
Earnings Before Interest and Taxes (ebit)	118	118
Earnings Before Interest and Taxes (ebitda)	2,539

After tax Income (+$)
Income Before Tax	-6,553
Tax Provision	--
Net Income From Continuing Ops	-6,553	-6,553
Net Income	-6,553
Net Income Applicable To Common Shares	-6,553

Non-recurring Events
Discontinued Operations	-
Extraordinary Items	-
Effect of Accounting Charges	-
Other Items	-
Non Recurring	-
Other Operating Expenses	121,559
Total Other Income/Expenses Net	71,484	6,638